

Swallowability and Dosing Compliance of Diazoxide Choline Extended-Release Tablets in Patients with Prader-Willi Syndrome

Scott Madsen¹, Mung Bernardo¹, Sherry Li¹, Michael Huang MD¹, Neil M. Cowen PhD¹

1. Soleno Therapeutics, Inc., Redwood City, CA, USA.

Abstract #34
United in HOPE
2025 PWS Conference
June 25-26, 2025
Phoenix, AZ

INTRODUCTION


Diazoxide choline extended-release (DCCR) tablets have recently been approved by the FDA as VYKAT™ XR for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).¹

DCCR had been evaluated in a series of three sequential Phase 3 studies in participants with PWS. The initial study, C601 or DESTINY PWS, was a double-blind, placebo controlled 13-week study.² This was followed by C602, which included a multi-year open-label treatment phase (C602-OLE) and a 16-week randomized withdrawal phase (C602-RWP).^{3,4} The final study in the sequence was open-label extension study C614.⁵ DCCR is administered orally once daily and tablets are to be taken whole, and not split, crushed or chewed. Dosing is based on weight.¹

METHODS


Three tablet strengths of DCCR containing 25 mg, 75 mg or 150 mg of diazoxide choline, were administered once daily to participants in the Phase 3 development program. DCCR tablets contain a polymer which, following administration, forms a hydrogel which erodes to release the active ingredient. The swelling of the tablet mass during the swallowing process was evaluated using artificial saliva and 2D x-ray radiography with AI-based data analysis (Figure 1) and in a separate study using calipers (Figure 2). Compliance with dosing was characterized based on the unused drug on returned study medication cards or IRB/IEC-approved study drug administration diaries / logs, and adverse events (AEs) related to challenges in swallowing the tablets were reviewed.

Figure 1. DCCR 2D X-Ray Radiograph



One 2D x-ray radiograph taken after **thirty seconds** of media exposure (**top image**) and after **15.5 minutes** of media exposure (**bottom image**). Segmentation results are overlaid on the greyscale data next to each respective radiograph (**a, c, e**). Radiographs focusing on the tablet length x height dimensions (**b, d, f**). Radiographs focusing on the tablet width x height dimensions. 25 mg (**a, b**), 75 mg (**c, d**), and 150 mg (**e, f**).

Figure 2. DCCR Exposure to Artificial Saliva - Caliper Measurements




a-c. Optical images taken **immediately** after coating the sample with artificial saliva
d-f. Optical images taken **after 15 minutes** of exposure to artificial saliva 25 mg (**a, d**), 75 mg (**b, e**), and 150 mg (**c, f**).

RESULTS

- During the simulated swallowing process there were small changes in tablet dimensions associated with the initial hydration of the tablet mass.
- The 25 mg tablet exhibited 1% increase in tablet length, 5% increase in tablet width, and 2.5% increase in tablet height; height results provided as an example in Figure 3.
- Both the 75 mg and 150 mg tablets increased by less than 2% in length, width, and height planes.

Figure 3. Maximum Percent Change in Tablet Height



- During the Phase 3 Program, a very high degree of compliance was observed across all studies (Table 1) and age categories, including the youngest age category (4 to <6 years).
- Mean compliance ranged from 94.2% to 99.5%.
- No AEs of dysphagia, choking, or other problems related to swallowability were reported.

Table 1. Dosing Compliance by Study and Treatment

Study	N	ACTIVE		PLACEBO		
		Mean (%)	Median (%)	N	Mean (%)	Median (%)
C601	84	97.2	98.9	42	98.2	99.5
C602-OLE	115	94.2	98.3	-	-	-
C602-RWP	38	99.5	100	39	98.8	100
C614	77	95.2	99.8	-	-	-

Abbreviations: OLE, open-label extension; RWP, randomized withdrawal phase.

REFERENCES

- VYKAT™ XR [package insert]. Soleno Therapeutics, Inc. 2025.
- Miller J, et al. *J Clin Endocrinol Metab.* 2023; 108:1676-1685.
- Miller J, et al. *Obesity (Silver Spring).* 2024; 32(2):252-261.
- Gevers EF, et al. ENDO 2024 Annual Meeting; Abstract 7519.
- Obryna K, et al. 2025 PES Annual Meeting; Abstract 1082.

CONCLUSIONS

- During the simulated swallowing process there were small changes in tablet dimensions associated with the initial hydration of the tablet mass.
- There was no evidence of issues with swallowability of DCCR tablets in children as young as 4 years as determined by dosing compliance in the Phase 3 development program and the lack of AEs that might reflect challenges with swallowability.
- DCCR tablets can be readily used to dose patients with PWS as young as 4 years old.

CONTACT

INFORMATION

For more information, contact Scott Madsen smadsen@soleno.life or Neil M. Cowen neil@soleno.life.

ELECTRONIC POSTER

Copies obtained through the QR code are for personal use only.

